AbCellera Biologics Holds Annual Shareholder Meeting

AbCellera Biologics ( (ABCL) ) has provided an update.

On June 12, 2025, AbCellera Biologics Inc. held its Annual Meeting of Shareholders, where key decisions were made regarding the election of directors, appointment of an accounting firm, and executive compensation. Shareholders approved the election of Carl L. G. Hansen and Michael Hayden as Class II directors, ratified KPMG LLP as the independent accounting firm, and endorsed executive compensation, reflecting continued support for the company’s strategic direction.

The most recent analyst rating on (ABCL) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on AbCellera Biologics stock, see the ABCL Stock Forecast page.

Spark’s Take on ABCL Stock

According to Spark, TipRanks’ AI Analyst, ABCL is a Neutral.

AbCellera Biologics’ stock score is primarily influenced by its financial challenges, including declining revenue and profitability. However, strong technical indicators and strategic advancements in drug development provide some optimism. The company’s robust liquidity position supports ongoing and future initiatives, but valuation concerns persist due to negative earnings and no dividend yield.

To see Spark’s full report on ABCL stock, click here.

More about AbCellera Biologics

AbCellera Biologics Inc. operates in the biotechnology industry, focusing on the discovery and development of antibody therapies. The company leverages its proprietary technology platform to identify antibodies for various diseases, aiming to accelerate the development of new treatments.

Average Trading Volume: 4,563,697

Technical Sentiment Signal: Sell

Current Market Cap: $964.1M

See more insights into ABCL stock on TipRanks’ Stock Analysis page.